Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Sep;33(9):1650–1651. doi: 10.1128/aac.33.9.1650

In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

J A García-Rodríguez 1, J E García Sánchez 1, M I García García 1, E García Sánchez 1, J L Muñoz Bellido 1
PMCID: PMC172726  PMID: 2817868

Abstract

The in vitro activities of amoxicillin, cefuroxime, ceftetrame, cefetamet, cefixime, tigemonam, erythromycin, roxithromycin, and dirithromycin against 30 clinical isolates of Campylobacter pylori were determined by an agar dilution technique. Roxithromycin and amoxicillin (MICs for 90% of isolates tested, 0.01 and 0.06 micrograms/ml, respectively) were the most active antibiotics tested, but all strains were susceptible to all antimicrobial agents tested.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buck G. E., Gourley W. K., Lee W. K., Subramanyam K., Latimer J. M., DiNuzzo A. R. Relation of Campylobacter pyloridis to gastritis and peptic ulcer. J Infect Dis. 1986 Apr;153(4):664–669. doi: 10.1093/infdis/153.4.664. [DOI] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. Tigemonam, an oral monobactam. Antimicrob Agents Chemother. 1988 Jan;32(1):84–91. doi: 10.1128/aac.32.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Czinn S., Carr H., Aronoff S. Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin. Antimicrob Agents Chemother. 1986 Aug;30(2):328–329. doi: 10.1128/aac.30.2.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Freland C., Massoubre B., Drugeon H. B. Sensibilité de Campylobacter pyloridis vis-à-vis des antibiotiques. Pathol Biol (Paris) 1987 Jun;35(5 Pt 2):809–812. [PubMed] [Google Scholar]
  5. Goodwin C. S., Armstrong J. A., Marshall B. J. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol. 1986 Apr;39(4):353–365. doi: 10.1136/jcp.39.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
  7. Hardy D. J., Hanson C. W., Hensey D. M., Beyer J. M., Fernandes P. B. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother. 1988 Nov;22(5):631–636. doi: 10.1093/jac/22.5.631. [DOI] [PubMed] [Google Scholar]
  8. Hornick R. B. Peptic ulcer disease: a bacterial infection? N Engl J Med. 1987 Jun 18;316(25):1598–1600. doi: 10.1056/NEJM198706183162509. [DOI] [PubMed] [Google Scholar]
  9. Humphreys H., Bourke S., Dooley C., McKenna D., Power B., Keane C. T., Sweeney E. C., O'Moráin C. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut. 1988 Mar;29(3):279–283. doi: 10.1136/gut.29.3.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McNulty C. A., Dent J. C., Ford G. A., Wilkinson S. P. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother. 1988 Nov;22(5):729–738. doi: 10.1093/jac/22.5.729. [DOI] [PubMed] [Google Scholar]
  11. McNulty C. A., Dent J. C. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):566–569. doi: 10.1007/BF01962617. [DOI] [PubMed] [Google Scholar]
  12. McNulty C. A., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):645–649. doi: 10.1136/bmj.293.6548.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Neu H. C., Chin N. X., Labthavikul P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):174–180. doi: 10.1128/aac.26.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neu H. C., Chin N. X., Labthavikul P. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother. 1986 Sep;30(3):423–428. doi: 10.1128/aac.30.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rathbone B. J., Wyatt J. I., Heatley R. V. Campylobacter pyloridis--a new factor in peptic ulcer disease? Gut. 1986 Jun;27(6):635–641. doi: 10.1136/gut.27.6.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rollason T. P., Stone J., Rhodes J. M. Spiral organisms in endoscopic biopsies of the human stomach. J Clin Pathol. 1984 Jan;37(1):23–26. doi: 10.1136/jcp.37.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 Jun 4;1(8336):1273–1275. [PubMed] [Google Scholar]
  18. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 Jun 4;1(8336):1273–1275. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES